Team Leadership

Best team in the world

For over 20 years, Dr. Todd has served in leadership for multi-cultural teams. He believes that high performing, cohesive teams are built through trust, communication, empowerment, complimentary skill sets and crystal clear, measurable, shared goals.

Field Innovation (2007 – 2016)

Dr. Todd designed and led programs to reach children in difficult contexts. His team developed relationships and partnerships, conducted training events, provided grants and worked to strengthen the capacity of churches to equip them for holistic ministry with children-at-risk in their communities. The team entered communities with a learning mindset, believing that local solutions are best for solving local challenges. From Myanmar, to Egypt they worked to find, honor, learn from, strengthen and multiply local models of holistic child development. The business practice of Reverse Innovation, together with the 4H theory of change, were central to this mobilization work in dozens of countries.

Haiti Medical Response Team (2010)

When the Haiti earthquake of 2010 struck, Dr. Todd was in Thailand. He was asked to assemble and lead a team of medical professionals to respond to the crisis. Within one week, he and a team of medical professionals were working to bring care to the injured. During their first week on the ground the team set up five mobile clinics and treated over 500 people. In addition, he coordinated the deployment of hundreds of thousands of dollars in medical supplies. 

Live 58: (2010 – )

In 2008 Scott was part of a small group of Christian leaders that met in Oxford, UK. They felt called to Isaiah 58 as the message God has for this generation. As a part of their work they produced a film which was shown in multiple languages in over a dozen countries. It led to a movement and the formation of the “58: Alliance” with stories of generosity stretching from Nepal to Idaho. Scott was privileged to be an executive producer of the film and serve as chair for the Live58 Board.

Child Survival Program (2005 – 2007)

Margaret was taking her goats out in the morning to graze when she heard a baby crying. Pushing her way through the marshy reeds she found Doreen covered in mud and struggling for survival with bruises around her neck. Margaret tried repeatedly to find the mother but when she took the baby to the local village chief she was told, “That’s your baby now.”

Margaret did her best to care for the baby, but then realized that Doreen’s continual illness and failure to gain weight was a bad sign. She told Scott, “I thought I would have to take her back to the swamp”.

Scott had the privilege of serving as the Director of a Child Survival Program. In two years he grew the number of programs from 34 to 174 operating in 26 countries. The Child Survival Program supported Margaret to care for Doreen and meet her medical needs (she was an HIV+ baby). Two years later, when visiting Doreen’s CSP in Uganda, Scott had a chance to visit Doreen. She was thriving and even able to help her “mother” (Margaret) with dishes and caring for the goats.

AIDS Initiative (2004 – 2008)

In 2004, Dr. Todd launched Compassion’s AIDS Initiative. He drafted the Blueprint and worked with global Health Specialists to understand, design and revise programs for prevention as well as treatment of children and caregivers with HIV/AIDS. One of the life-changing moments in this work came in February 2005 when he met Jacqueline (photo on right).

After Jacqueline’s death he made a promise: “I will do whatever I can with whatever influence God grants to not be too late for the rest of them”. As a team they worked tirelessly and within two years every child in Compassion’s African programs that needed antiretroviral medicine was receiving that medicine.

But access to treatment is the easy part of the work. Ensuring that children continue taking their medicines even after they feel healthy again is the greater challenge. To learn more about the motivators and barriers to adherence (taking medicine as prescribed) he oversaw more than 100 interviews with children, parents, pastors and other medical professionals. In Uganda they conducted a formal study to track adherence over time. The lessons learned were used to shape program design and practice and, as a result, adherence and survival rates are unprecedented.

This work would not have been possible without the partnership, experience and friendship with one of his closest colleagues at that time – Dr. Alemayehu Habtegabriel.  He and the health specialists across Africa were pioneers in comprehensive, church-facilitated pediatric AIDS care.

President’s Award for Excellence in Undergraduate Teaching (2002)

In 2002, Dr. Todd was awarded the President’s Award for Excellence in Undergraduate Education based on teaching in Immunology, Molecular and Cellular Biology and Introduction to Biology.  He was the youngest professor ever to receive this award.

Patent (2002)

Dr. Todd’s research team discovered a domain on CD81, a cell surface protein, that serves as a binding site of hepatitis C virus E2. In collaboration with a team of biochemists, they developed a series of small molecule inhibitors that block the binding event. The molecular structure of those inhibitors offered a lead compound in the discovery of a novel class of therapeutics to treat HCV infection.

Compositions and methods for the treatment of hepatitis C virus infection

United States Patent # 7,208,628

Filed: May 13, 2002

Published Research (1993 – 2004)

The research articles below are published in peer-reviewed professional journals. The links will take you to the abstract and in some cases the full article if available.

CD81 associates with 14-3-3 in a redox-regulated palmitoylation-dependent manner.

Clark KL, Oelke A, Johnson ME, Eilert KD, Simpson PC, Todd SC.

J Biol Chem. 2004 May 7;279(19):19401-6. Epub 2004 Feb 13.

Small molecule inhibition of hepatitis C virus E2 binding to CD81.

VanCompernolle SE, Wiznycia AV, Rush JR, Dhanasekaran M, Baures PW, Todd SC.

Virology. 2003 Sep 15;314(1):371-80.

Expression and function of formyl peptide receptors on human fibroblast cells.

VanCompernolle SE, Clark KL, Rummel KA, Todd SC.

J Immunol. 2003 Aug 15;171(4):2050-6.

PGRL is a major CD81-associated protein on lymphocytes and distinguishes a new family of cell surface proteins.

Clark KL, Zeng Z, Langford AL, Bowen SM, Todd SC.

J Immunol. 2001 Nov 1;167(9):5115-21.

Anti-CD81 activates LFA-1 on T cells and promotes T cell-B cell collaboration.

VanCompernolle SE, Levy S, Todd SC.

Eur J Immunol. 2001 Mar;31(3):823-31.

Differential expression of murine CD81 highlighted by new anti-mouse CD81 monoclonal antibodies.

Maecker HT, Todd SC, Kim EC, Levy S.

Hybridoma. 2000 Feb;19(1):15-22.

Sequences and expression of six new members of the tetraspanin/TM4SF family.

Todd SC, Doctor VS, Levy S.

Biochim Biophys Acta. 1998 Jul 30;1399(1):101-4.

CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system.

Levy S, Todd SC, Maecker HT.

Annu Rev Immunol. 1998;16:89-109. Review.

The tetraspanin superfamily: molecular facilitators.

Maecker HT, Todd SC, Levy S.

FASEB J. 1997 May;11(6):428-42. Review.

CD81 expressed on human thymocytes mediates integrin activation and interleukin 2-dependent proliferation.

Todd SC, Lipps SG, Crisa L, Salomon DR, Tsoukas CD.

J Exp Med. 1996 Nov 1;184(5):2055-60.

EBV induces proliferation of immature human thymocytes in an IL-2-mediated response.

Todd SC, Tsoukas CD.

J Immunol. 1996 Jun 1;156(11):4217-23.

Characterization of a 70-kDa, EBV gp350/220-binding protein on HSB-2 T cells.

Hedrick JA, Lao Z, Lipps SG, Wang Y, Todd SC, Lambris JD, Tsoukas CD.

J Immunol. 1994 Nov 15;153(10):4418-26.

CD1+ human thymocytes proliferate in response to superantigen staphylococcal enterotoxin B1.

Todd SC, Baccala R, Hedrick JA, Theofilopoulos AN, Tsoukas CD.

J Immunol. 1994 Sep 1;153(5):2038-45.

Characterization of the EBV/C3d receptor on the human Jurkat T cell line: evidence for a novel transcript.

Sinha SK, Todd SC, Hedrick JA, Speiser CL, Lambris JD, Tsoukas CD.

J Immunol. 1993 Jun 15;150(12):5311-20.